Inflammatory serum proteins are severely altered in metastatic gastric adenocarcinoma patients from the Chinese population

Jiangnan Wang, Rong Ma, Ashok Kumar Sharma, Mingfang He, Jing Xue, Jianzhong Wu, Boying Dun, Gang Li, Xiaoxiao Wang, Minghua Ji, Jin-Xiong She, Jinhai Tang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background Inflammation is one of the major hallmarks of cancer. This study was designed to profile a panel of inflammatory mediators in gastric adenocarcinoma (GA) and to identify their potential differences separately in metastatic and non-metastatic patient subgroups. Methods Serum samples from 216 GA patients and 333 healthy controls from China were analyzed for six proteins using the Luminex multiplex assay. Results The serum levels for all the six proteins were significantly elevated in metastatic GA compared to non-metastatic GA. Two acute phase proteins (SAA and CRP) and a CXC chemokine (GRO) were significantly elevated in metastatic GA (p <0.01) but smaller changes were observed in non-metastatic GA compared to healthy controls. OPN is moderately increased in non-metastatic GA (2.05-fold) and more severely elevated in metastatic GA (3.34-fold). Surprisingly, soluble VCAM1 and AGP were significantly lower in both non-metastatic and metastatic GA patients compared to controls. Several individual proteins were shown to possess moderate diagnostic value for non-metastatic GA (AUC = 0.786, 0.833, 0.823 for OPN, sVCAM1 and AGP, respectively) and metastatic GA (AUC = 0.931, 0.720, 0.834 and 0.737 for OPN, sVCAM1, SAA and CRP, respectively). However, protein combinations further improve the diagnostic potential for both non-metastatic GA (best AUC = 0.946) and metastatic GA (best AUC = 0.963). The protein combination with best AUC value for both comparisons is OPN+sVCAM1+AGP+SAA. Conclusions These results suggest that several serum proteins are directly related to the severity of gastric cancer. Overall, stronger associations are observed with metastatic than non-metastatic GA as the protein changes are greater with the metastatic status. A combination of these serum proteins may serve as non-invasive markers to assess the severity status and stage of gastric cancer.

Original languageEnglish (US)
Article numbere0123985
JournalPloS one
Volume10
Issue number4
DOIs
StatePublished - Apr 17 2015

Fingerprint

adenocarcinoma
blood proteins
Blood Proteins
Stomach
stomach
Adenocarcinoma
Population
Proteins
Area Under Curve
CXC Chemokines
Acute-Phase Proteins
stomach neoplasms
proteins
Assays
Stomach Neoplasms
acute phase proteins
disease diagnosis
Serum
China
inflammation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Inflammatory serum proteins are severely altered in metastatic gastric adenocarcinoma patients from the Chinese population. / Wang, Jiangnan; Ma, Rong; Sharma, Ashok Kumar; He, Mingfang; Xue, Jing; Wu, Jianzhong; Dun, Boying; Li, Gang; Wang, Xiaoxiao; Ji, Minghua; She, Jin-Xiong; Tang, Jinhai.

In: PloS one, Vol. 10, No. 4, e0123985, 17.04.2015.

Research output: Contribution to journalArticle

Wang, Jiangnan ; Ma, Rong ; Sharma, Ashok Kumar ; He, Mingfang ; Xue, Jing ; Wu, Jianzhong ; Dun, Boying ; Li, Gang ; Wang, Xiaoxiao ; Ji, Minghua ; She, Jin-Xiong ; Tang, Jinhai. / Inflammatory serum proteins are severely altered in metastatic gastric adenocarcinoma patients from the Chinese population. In: PloS one. 2015 ; Vol. 10, No. 4.
@article{6ad2e73b03d943fc93500269c98eac7a,
title = "Inflammatory serum proteins are severely altered in metastatic gastric adenocarcinoma patients from the Chinese population",
abstract = "Background Inflammation is one of the major hallmarks of cancer. This study was designed to profile a panel of inflammatory mediators in gastric adenocarcinoma (GA) and to identify their potential differences separately in metastatic and non-metastatic patient subgroups. Methods Serum samples from 216 GA patients and 333 healthy controls from China were analyzed for six proteins using the Luminex multiplex assay. Results The serum levels for all the six proteins were significantly elevated in metastatic GA compared to non-metastatic GA. Two acute phase proteins (SAA and CRP) and a CXC chemokine (GRO) were significantly elevated in metastatic GA (p <0.01) but smaller changes were observed in non-metastatic GA compared to healthy controls. OPN is moderately increased in non-metastatic GA (2.05-fold) and more severely elevated in metastatic GA (3.34-fold). Surprisingly, soluble VCAM1 and AGP were significantly lower in both non-metastatic and metastatic GA patients compared to controls. Several individual proteins were shown to possess moderate diagnostic value for non-metastatic GA (AUC = 0.786, 0.833, 0.823 for OPN, sVCAM1 and AGP, respectively) and metastatic GA (AUC = 0.931, 0.720, 0.834 and 0.737 for OPN, sVCAM1, SAA and CRP, respectively). However, protein combinations further improve the diagnostic potential for both non-metastatic GA (best AUC = 0.946) and metastatic GA (best AUC = 0.963). The protein combination with best AUC value for both comparisons is OPN+sVCAM1+AGP+SAA. Conclusions These results suggest that several serum proteins are directly related to the severity of gastric cancer. Overall, stronger associations are observed with metastatic than non-metastatic GA as the protein changes are greater with the metastatic status. A combination of these serum proteins may serve as non-invasive markers to assess the severity status and stage of gastric cancer.",
author = "Jiangnan Wang and Rong Ma and Sharma, {Ashok Kumar} and Mingfang He and Jing Xue and Jianzhong Wu and Boying Dun and Gang Li and Xiaoxiao Wang and Minghua Ji and Jin-Xiong She and Jinhai Tang",
year = "2015",
month = "4",
day = "17",
doi = "10.1371/journal.pone.0123985",
language = "English (US)",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Inflammatory serum proteins are severely altered in metastatic gastric adenocarcinoma patients from the Chinese population

AU - Wang, Jiangnan

AU - Ma, Rong

AU - Sharma, Ashok Kumar

AU - He, Mingfang

AU - Xue, Jing

AU - Wu, Jianzhong

AU - Dun, Boying

AU - Li, Gang

AU - Wang, Xiaoxiao

AU - Ji, Minghua

AU - She, Jin-Xiong

AU - Tang, Jinhai

PY - 2015/4/17

Y1 - 2015/4/17

N2 - Background Inflammation is one of the major hallmarks of cancer. This study was designed to profile a panel of inflammatory mediators in gastric adenocarcinoma (GA) and to identify their potential differences separately in metastatic and non-metastatic patient subgroups. Methods Serum samples from 216 GA patients and 333 healthy controls from China were analyzed for six proteins using the Luminex multiplex assay. Results The serum levels for all the six proteins were significantly elevated in metastatic GA compared to non-metastatic GA. Two acute phase proteins (SAA and CRP) and a CXC chemokine (GRO) were significantly elevated in metastatic GA (p <0.01) but smaller changes were observed in non-metastatic GA compared to healthy controls. OPN is moderately increased in non-metastatic GA (2.05-fold) and more severely elevated in metastatic GA (3.34-fold). Surprisingly, soluble VCAM1 and AGP were significantly lower in both non-metastatic and metastatic GA patients compared to controls. Several individual proteins were shown to possess moderate diagnostic value for non-metastatic GA (AUC = 0.786, 0.833, 0.823 for OPN, sVCAM1 and AGP, respectively) and metastatic GA (AUC = 0.931, 0.720, 0.834 and 0.737 for OPN, sVCAM1, SAA and CRP, respectively). However, protein combinations further improve the diagnostic potential for both non-metastatic GA (best AUC = 0.946) and metastatic GA (best AUC = 0.963). The protein combination with best AUC value for both comparisons is OPN+sVCAM1+AGP+SAA. Conclusions These results suggest that several serum proteins are directly related to the severity of gastric cancer. Overall, stronger associations are observed with metastatic than non-metastatic GA as the protein changes are greater with the metastatic status. A combination of these serum proteins may serve as non-invasive markers to assess the severity status and stage of gastric cancer.

AB - Background Inflammation is one of the major hallmarks of cancer. This study was designed to profile a panel of inflammatory mediators in gastric adenocarcinoma (GA) and to identify their potential differences separately in metastatic and non-metastatic patient subgroups. Methods Serum samples from 216 GA patients and 333 healthy controls from China were analyzed for six proteins using the Luminex multiplex assay. Results The serum levels for all the six proteins were significantly elevated in metastatic GA compared to non-metastatic GA. Two acute phase proteins (SAA and CRP) and a CXC chemokine (GRO) were significantly elevated in metastatic GA (p <0.01) but smaller changes were observed in non-metastatic GA compared to healthy controls. OPN is moderately increased in non-metastatic GA (2.05-fold) and more severely elevated in metastatic GA (3.34-fold). Surprisingly, soluble VCAM1 and AGP were significantly lower in both non-metastatic and metastatic GA patients compared to controls. Several individual proteins were shown to possess moderate diagnostic value for non-metastatic GA (AUC = 0.786, 0.833, 0.823 for OPN, sVCAM1 and AGP, respectively) and metastatic GA (AUC = 0.931, 0.720, 0.834 and 0.737 for OPN, sVCAM1, SAA and CRP, respectively). However, protein combinations further improve the diagnostic potential for both non-metastatic GA (best AUC = 0.946) and metastatic GA (best AUC = 0.963). The protein combination with best AUC value for both comparisons is OPN+sVCAM1+AGP+SAA. Conclusions These results suggest that several serum proteins are directly related to the severity of gastric cancer. Overall, stronger associations are observed with metastatic than non-metastatic GA as the protein changes are greater with the metastatic status. A combination of these serum proteins may serve as non-invasive markers to assess the severity status and stage of gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=84929485216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929485216&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0123985

DO - 10.1371/journal.pone.0123985

M3 - Article

C2 - 25884401

AN - SCOPUS:84929485216

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e0123985

ER -